Correction to: Leukemia https://doi.org/10.1038/s41375-024-02159-0, published online 29 January 2024
Following publication of the article, the authors realized that several data points in Figure S3B and the accompanying manuscript text were incorrect. This oversight has been addressed and the corrected figure has been added.
-
1.
Supplementary information, Figure S3B: The percentage of patients with grade 3-4 TE-AOEs from the PACE CP-CML group was inaccurately rounded to 12%; the correct percentage is 11%. In addition, we have corrected the error in the manuscript on page 477 in the Safety outcomes section. The revised statement is below:
Grade 3-4 TE-AOEs were 11% in PACE and 5% in OPTIC, and serious TE-AOEs were 15% in PACE and 4% in OPTIC (Fig. S3).
-
2.
Supplementary information, Figure S3B: The number of patients with serious TE-AOEs in the PACE CP-CML group was cited incorrectly as 9; the correct number of patients is 40.
The corrected figure S3B is now included in the supplementary information.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Jabbour, E., Apperley, J., Cortes, J. et al. Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38, 2291 (2024). https://doi.org/10.1038/s41375-024-02385-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-024-02385-6
